A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First‐Line Exemestane: Results From a Prospective Study

[1]  G. Arpino,et al.  Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[2]  D. Atchley,et al.  Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post‐menopausal female volunteers , 2017, Journal of clinical pharmacy and therapeutics.

[3]  P. Lazarus,et al.  Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives , 2017, Pharmacology research & perspectives.

[4]  Chiun-Sheng Huang,et al.  Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer , 2017, Oncotarget.

[5]  A. Trumpp,et al.  Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer , 2017, Nature Genetics.

[6]  Nicholas J. Seewald,et al.  Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer , 2016, The Pharmacogenomics Journal.

[7]  P. Hrelia,et al.  Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome , 2016, Tumor Biology.

[8]  Luisa Mola Morales,et al.  Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer , 2016, PloS one.

[9]  Aiko Sueta,et al.  Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer , 2016, Cancer science.

[10]  Lang Li,et al.  Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover , 2015, Breast Cancer Research and Treatment.

[11]  Ji-ping Wang,et al.  Estrogen metabolites and breast cancer , 2015, Steroids.

[12]  M. Hutz,et al.  Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis , 2015, BMC Medicine.

[13]  P. Neven,et al.  CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial , 2015, Breast Cancer Research and Treatment.

[14]  Xuefeng Zhang,et al.  Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells. , 2015, Oncology reports.

[15]  Jie Shen,et al.  Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C Polymorphisms and Overall Survival of Breast Cancer Patients after Tamoxifen Therapy , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[16]  Fabrice André,et al.  Rationale for targeting fibroblast growth factor receptor signaling in breast cancer , 2015, Breast Cancer Research and Treatment.

[17]  Keat Wei,et al.  The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients , 2014, Pharmacogenetics and genomics.

[18]  C. Caldon,et al.  Estrogen Signaling and the DNA Damage Response in Hormone Dependent Breast Cancers , 2014, Front. Oncol..

[19]  M. Michalska,et al.  Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and triple-negative breast cancer in Polish women , 2014, Clinical and Experimental Medicine.

[20]  P. Neven,et al.  Aromatase inhibitors in the breast cancer clinic: focus on exemestane. , 2014, Endocrine-Related Cancer.

[21]  R. González-Sarmiento,et al.  Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients , 2014, Clinical and Translational Oncology.

[22]  Jian-hua Zhou,et al.  A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma , 2013, International journal of molecular sciences.

[23]  K. Hemminki,et al.  Genetic Variants in Hormone-Related Genes and Risk of Breast Cancer , 2013, PloS one.

[24]  Steffi Oesterreich,et al.  Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer , 2013, Breast Cancer Research and Treatment.

[25]  A. Lluch,et al.  Associations between Aromatase CYP19 rs10046 Polymorphism and Breast Cancer Risk: From a Case-Control to a Meta-Analysis of 20,098 Subjects , 2013, PloS one.

[26]  A. Brodie,et al.  Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer , 2014, Breast Cancer Research.

[27]  P. Bruzzi,et al.  Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole , 2012, Breast Cancer Research and Treatment.

[28]  Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer. , 2012, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[29]  A. Jaiswal,et al.  The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer , 2012, Breast Cancer Research and Treatment.

[30]  S. Marsh,et al.  Pharmacogenomics of third-generation aromatase inhibitors , 2012, Expert opinion on pharmacotherapy.

[31]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[32]  A. Howell,et al.  Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients , 2012, Breast Cancer Research and Treatment.

[33]  Jian-Ting Zhang,et al.  Human ABCG2: structure, function, and its role in multidrug resistance. , 2012, International journal of biochemistry and molecular biology.

[34]  C. Berking,et al.  Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor , 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[35]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[36]  Yusuke Nakamura,et al.  Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  O. Kallioniemi,et al.  Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. , 2010 .

[38]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Ullrich,et al.  A single nucleotide change in the mouse genome accelerates breast cancer progression. , 2010, Cancer research.

[40]  Theodoros N. Sergentanis,et al.  XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis , 2010, Breast Cancer Research and Treatment.

[41]  M. Climent,et al.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole , 2010, BMC Cancer.

[42]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[43]  M. Piccart,et al.  Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Uitterlinden,et al.  Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. , 2008, Endocrinology.

[45]  P. Watkins,et al.  Association of Breast Cancer Resistance Protein/ABCG2 Phenotypes and Novel Promoter and Intron 1 Single Nucleotide Polymorphisms , 2008, Drug Metabolism and Disposition.

[46]  J. Foekens,et al.  Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. , 2008, Endocrine-related cancer.

[47]  B. Lloveras,et al.  A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma , 2008, Clinical Cancer Research.

[48]  M. Bani,et al.  Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients , 2008, Breast Cancer Research and Treatment.

[49]  Mikko Niemi,et al.  Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.

[50]  D. Mellström,et al.  The impact of estradiol on bone mineral density is modulated by the specific estrogen receptor-alpha cofactor retinoblastoma-interacting zinc finger protein-1 insertion/deletion polymorphism. , 2007, The Journal of clinical endocrinology and metabolism.

[51]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[52]  R. Lafrenie,et al.  Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Ioannidis,et al.  Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. , 2006, Journal of the National Cancer Institute.

[54]  J. Nährig,et al.  FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Dowsett,et al.  Mechanisms of resistance to aromatase inhibitors , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[56]  B. Ponder,et al.  Polymorphisms associated with circulating sex hormone levels in postmenopausal women. , 2005, Journal of the National Cancer Institute.

[57]  C. Ulrich,et al.  Association of CYP17, CYP19, CYP1B1, and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal Women , 2004, Cancer Epidemiology Biomarkers & Prevention.

[58]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[59]  H. Höfler,et al.  Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. , 2002, Cancer research.

[60]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[61]  P Vineis,et al.  XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. , 2001, Carcinogenesis.